Not surprised that GSK abandoned IV Relenza. Their profit is from new vaccines every year. Better for GSK than to find a heap of generic IV Relenza look-a-like vaccine alternatives flooding their market when the patent expires in 2014. GSK cannot serve BTA when it has only one master - GSK.
- Forums
- ASX - By Stock
- BTA
- lani, iv relenza,flumist breaking news reuters
lani, iv relenza,flumist breaking news reuters, page-6
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)